Western Financial Corp CA Buys New Shares in Eli Lilly and Company $LLY

Key Points

• Western Financial Corp CA bought a new stake of 3,146 shares in Eli Lilly (LLY) in Q4, valued at about $3.38 million — roughly 1.3% of its portfolio and the firm's 15th-largest holding.
• Eli Lilly is aggressively rolling out its oral GLP‑1 weight‑loss pill Foundayo via retail (including Amazon Pharmacy), telehealth and same‑day delivery with competitive cash and insurer pricing, which should accelerate prescriptions and revenue uptake.
• However, the emergence of low‑cost semaglutide generics in India and pricing/feature moves from competitors like Novo Nordisk could pressure Lilly’s market share and future margins.

Western Financial Corp CA bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 3,146 shares of the company's stock, valued at approximately $3,381,000. Eli Lilly and Company comprises approximately 1.3% of Western Financial Corp CA's investment portfolio, making the stock its 15th biggest holding.

Several other large investors have also recently bought and sold shares of LLY. Maryland Capital Advisors Inc. acquired a new position in Eli Lilly and Company during the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC raised its stake in shares of Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after buying an additional 16 shares in the last quarter. Evolution Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $29,000. Steph & Co. raised its stake in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company's stock valued at $30,000 after buying an additional 29 shares in the last quarter. Finally, 10Elms LLP raised its stake in shares of Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after buying an additional 10 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly’s Foundayo is being pushed into wide retail and delivery channels (Amazon Pharmacy kiosks/same‑day delivery, retail pharmacies, WeightWatchers, GoodRx and telehealth partners), which should accelerate prescriptions and revenue uptake. Amazon to stock Lilly's new weight-loss pill
• Positive Sentiment: Lilly has rolled Foundayo out broadly across the U.S. via LillyDirect, telehealth providers and retail partners, enabling same/next‑day delivery and integrated care — a distribution push that supports faster adoption. Eli Lilly Expands Foundayo Access
• Positive Sentiment: Foundayo’s pricing strategy: list/self‑pay around $149/month but as low as ~$25/month with commercial coverage — competitive cash pricing and insurer access may broaden the addressable market and improve uptake vs. injectable alternatives. Foundayo now available in the U.S. (PR Newswire)
• Positive Sentiment: Lilly is leveraging telehealth (Lilly Direct, Ro, WeightWatchers Med+ partnerships) to speed prescribing and adherence, which can raise early prescription volumes and lower friction for patients starting therapy. Lilly launches oral GLP‑1 through telehealth
• Neutral Sentiment: Analysts and media frame Foundayo as a strategic inflection point for Lilly; some firms remain bullish into earnings, supporting sentiment but leaving execution and longer‑term pricing dynamics as watch points. Foundayo is a turning point (Barron's)
• Negative Sentiment: In India a surge of low‑cost generic semaglutide copies has begun to erode Lilly’s market share (Mounjaro and other offerings), with Lilly’s share down month‑over‑month — an early sign of pricing and share pressure in emerging markets that could foreshadow global margin headwinds as patents expire. Generics flood India (CNBC)
• Negative Sentiment: Market chatter and reports highlight growing pressure from cheaper semaglutide generics in India and elsewhere; Lilly has responded, but ongoing generic competition and pricing moves by rivals could compress future volumes/prices. Market Chatter: generics gain ground (Yahoo)
• Negative Sentiment: Competitor Novo Nordisk’s tweaks (higher‑dose Wegovy at a lower monthly price and improved convenience) intensify pricing and convenience competition in obesity treatment, which could limit Lilly’s pricing power and share gains. Novo's higher‑dose Wegovy move (Yahoo)

Eli Lilly and Company Stock Up 0.3%

LLY opened at $956.49 on Friday. The firm's 50-day simple moving average is $985.96 and its 200-day simple moving average is $972.98. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The firm has a market cap of $903.71 billion, a price-to-earnings ratio of 41.68, a PEG ratio of 1.11 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the firm earned $5.32 EPS. The firm's quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research note on Thursday, February 5th. Barclays began coverage on shares of Eli Lilly and Company in a research note on Thursday, February 19th. They issued an "overweight" rating and a $1,350.00 price objective for the company. UBS Group restated a "buy" rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Finally, Jefferies Financial Group set a $1,300.00 price objective on shares of Eli Lilly and Company and gave the company a "buy" rating in a research note on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,222.22.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.